Lytenava (bevacizumab-vikg) / Outlook Therap 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lytenava (bevacizumab-vikg) / Outlook Therap
NORSE EIGHT, NCT06190093: A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects with Neovascular Age-related Macular Degeneration (AMD)

Completed
3
400
US
bevacizumab, ONS-5010, ranibizumab
Outlook Therapeutics, Inc.
Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
11/24
12/24
NORSE SEVEN, NCT05112861: A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders

Active, not recruiting
3
120
US
bevacizumab, ONS-5010
Outlook Therapeutics, Inc.
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion, Diabetic Macular Edema
03/25
03/25

Download Options